X0306 4 2020-11-04 false 0000842023 BIO-TECHNE Corp TECH 0001603594 Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS MN 55413 false true false false Chief Financial Officer Common Stock 2020-11-04 4 M false 7100.00 108.49 A 16237.00 D Common Stock 2020-11-04 4 S false 1555.00 272.7099 D 14682.00 D Common Stock 2020-11-04 4 S false 2745.00 273.6454 D 11937.00 D Common Stock 2020-11-04 4 S false 1600.00 274.534 D 10337.00 D Common Stock 2020-11-04 4 S false 1200.00 275.7931 D 9137.00 D Common Stock 2020-11-05 4 M false 8809.00 108.49 A 17946.00 D Common Stock 2020-11-05 4 S false 398.00 280.277 D 17548.00 D Common Stock 2020-11-05 4 S false 203.00 281.2741 D 17345.00 D Common Stock 2020-11-05 4 S false 1674.00 282.5203 D 15671.00 D Common Stock 2020-11-05 4 S false 325.00 283.64 D 15346.00 D Common Stock 2020-11-05 4 S false 1630.00 285.1165 D 13716.00 D Common Stock 2020-11-05 4 S false 121.00 287.1493 D 13595.00 D Common Stock 2020-11-05 4 S false 3249.00 287.9804 D 10346.00 D Common Stock 2020-11-05 4 S false 359.00 289.3858 D 9987.00 D Common Stock 2020-11-05 4 S false 750.00 291.0627 D 9237.00 D Common Stock 2020-11-05 4 S false 100.00 293.66 D 9137.00 D Stock Option (Right to Buy) 108.49 2020-11-04 4 M false 7100.00 0.00 D 2022-08-07 Common Stock 7100.00 7100.00 D Stock Option (Right to Buy) 108.49 2020-10-05 4 M false 8809.00 0.00 D 2022-08-07 Common Stock 8809.00 0.00 D Stock Option (Right to Buy) 106.59 2023-08-18 Common Stock 30400.00 30400.00 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 40533.00 40533.00 D Stock Options (Right to buy) 125.05 2024-08-09 Common Stock 24460.00 24460.00 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 32613.00 32613.00 D Restricted Stock Units Common Stock 3383.00 3383.00 D Stock Options (Right to buy) 177.32 2025-08-08 Common Stock 18066.00 18066.00 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 24089.00 24089.00 D Restricted Stock Units Common Stock 3938.00 3938.00 D Stock Option (Right to Buy) 190.41 2026-08-07 Common Stock 19936.00 19936.00 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 26581.00 26581.00 D Restricted Stock Unit Common Stock 3219.00 3219.00 D Stock Option (Right to Buy) 267.87 2027-08-05 Common Stock 14360.00 14360.00 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 19147.00 19147.00 D Stock Options (Right to buy) 267.87 2027-08-05 Common Stock 8325.00 8325.00 D Stock Options (Right to buy) 267.87 2027-08-05 Common Stock 8325.00 8325.00 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.21 to $273.20, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.23 to $274.19, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.24 to $275.045, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.38 to $276.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.84 to $280.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.00 to $281.55, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.57 to $284.48, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.00 to $285.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.67 to $287.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.68 to $288.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.00 to $289.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $290.66 to $291.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.66 to $293.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Fully exercisable. Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator. Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024. Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. /s/ Brenda S. Furlow, attorney in fact for James Hippel pursuant to Power of Attorney previously filed 2020-11-06